Form 4: Revance Therapeutics Director Vlad Coric Disposes of Shares Following Merger Agreement

Director Vlad Coric reports the disposal of Revance Therapeutics shares due to the merger with Crown Laboratories, Inc.

Summary

• Vlad Coric, a director of Revance Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On February 4, 2025, Coric disposed of 5,784 shares of common stock at a price of $3.65 per share, totaling $21,111.60.
• These shares were tendered as part of a cash tender offer by Crown Laboratories, Inc. following the Amended and Restated Agreement and Plan of Merger dated December 7, 2024.
• On February 6, 2025, Coric also disposed of 15,000 shares of common stock.
• These shares were part of a restricted stock award that was canceled and converted into the right to receive $3.65 per share as per the merger agreement.
• Following these transactions, Coric's direct ownership of Revance Therapeutics common stock is reported as zero shares.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document primarily reports the execution of a previously announced merger agreement. It's a procedural filing rather than an indication of positive or negative business performance.

Future Outlook

The document does not contain any specific forward-looking statements beyond the completion of the merger.

Industry Context

This announcement reflects the completion of a merger, a common occurrence in the biotechnology and pharmaceutical industries as companies seek to consolidate resources, expand product portfolios, or gain access to new technologies.

Comparison to Industry Standards

• Mergers and acquisitions are a common strategy in the biotech industry.
• Comparable transactions include Allergan's acquisition by AbbVie and Celgene's acquisition by Bristol-Myers Squibb.
• These deals often involve a cash tender offer followed by a merger to acquire all outstanding shares.

Stakeholder Impact

• Shareholders received $3.65 per share as part of the merger agreement.
• Non-employee board members received cash for their unvested restricted stock awards.

Key Dates

Keywords

Form 4, Revance Therapeutics, Vlad Coric, Merger Agreement, Crown Laboratories, Share Disposal, Beneficial Ownership, RVNC